Core Insights - The healthcare sector has significantly outperformed the broader market, with the S&P 500 Health Care Sector index rising approximately 5.1% over the past month compared to a 2.3% increase in the S&P 500 index, primarily driven by blockbuster drugs [1] Company Highlights - Eli Lilly's GLP-1 medication, tirzepatide, became the best-selling drug globally in the third quarter, contributing to a 9.1% increase in its stock price over the past month [3] - Eli Lilly's current market capitalization stands at $943 billion, with a stock price range between $993.00 and $1011.00 [4] - Johnson & Johnson announced the acquisition of Halda Therapeutics, a company focused on developing oral therapies for solid tumors, leading to an 8.6% increase in its stock price over the past month [5] - AbbVie's Skyrizi and Rinvoq saw substantial sales growth, with Skyrizi sales rising 46.8% to $4.7 billion and Rinvoq sales increasing 35.3% to nearly $2.2 billion in the third quarter, contributing to a 4.3% rise in its stock price [6] - Merck's Keytruda achieved quarterly sales exceeding $8 billion for the first time, resulting in an 18.2% increase in its stock price over the past month [7]